Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. The Prognostic Value of CTC–WBC Clusters in Patients With RCC
  2. Antibiotic Use Is Associated With Survival in RCC Patients Treated With Immunotherapy
  3. Racial Differences in Clinical Outcomes in Metastatic RCC Treated With ICIs
  4. Sunitinib Is Noninferior to Sunitinib/Nephrectomy in Metastatic RCC
  5. IRAEs as Biomarkers in Metastatic RCC Treated With ICIs
  6. Pancreatic Metastases Predict Improved Survival in Patients With Advanced RCC Treated With Systemic Therapy
  7. Stereotactic Radiotherapy With Immunotherapy or Targeted Therapy for Metastatic Renal Cell Carcinoma
  8. Lenvatinib + Pembrolizumab in Treatment-Naive or Previously Treated mRCC
  9. Gene Expression Signature Correlates With Outcomes in mRCC Patients Treated With Everolimus ± a Vascular Disrupting Agent
  10. Nivolumab Plus Cabozantinib for Patients With Non-Clear Cell Renal Cell Carcinoma

Elsewhere

Recently Updated